Current and emerging therapies for the lysosomal storage disorders. - Wikidata - awgldk - TriplyDB

Current and emerging therapies for the lysosomal storage disorders.

Current and emerging therapies for the lysosomal storage disorders.

http://www.wikidata.org/entity/Q36302871

about

Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV Chitotriosidase in the Pathogenesis of Inflammation, Interstitial Lung Diseases and COPD Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease A retro-inverso TAT-like peptide designed to deliver cysteamine to cells.Pharmacological chaperone therapy for lysosomal storage diseases.Advances in genetics: what are the benefits for patients?Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options.Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling.Human chitinases and chitinase-like proteins as indicators for inflammation and cancer Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.Signs and symptoms in Gaucher Disease: priority nursing diagnoses.

P2860

Q24655743-B49912E1-49B0-4E95-9165-ACEB203B045C Q28384802-5FAEEDE0-C184-4355-AF0C-F897A4DD4B5B Q28755163-E7CFD49F-9301-434E-8147-86FC5915010C Q33292772-6C5FEC80-99E2-4E8B-A1AD-0E9785F58D33 Q33693446-A18BAFB9-FBA5-42E4-BE9A-8FE3A516FF0D Q35214286-667BE041-1BBB-44CF-A4B9-38E8BB3A24C4 Q36337173-CC0576B2-4B83-45A9-9A6D-764B43CE30F0 Q36592822-EE6C4449-9654-4E67-813B-826A28875735 Q36944628-333F4579-8F2E-4FF2-8027-749376C0EDBE Q37280948-4893168D-BAE2-41D9-B041-F0E0730D1F8E Q38172827-9C90E475-8A0A-4072-BC4B-7495136E39CB Q42367666-0373BE7C-D34E-4E04-B0B1-57C578F9B217 Q47554850-4BA81593-8582-41B5-A5EB-E68B8D0A9EF8

P2860

Current and emerging therapies for the lysosomal storage disorders.

http://www.wikidata.org/entity/Q36302871

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Current and emerging therapies for the lysosomal storage disorders.

@ast

Current and emerging therapies for the lysosomal storage disorders.

@en

type

label

Current and emerging therapies for the lysosomal storage disorders.

@ast

Current and emerging therapies for the lysosomal storage disorders.

@en

prefLabel

Current and emerging therapies for the lysosomal storage disorders.

@ast

Current and emerging therapies for the lysosomal storage disorders.

@en

P1433

Q36302871-271186F0-5A31-496B-A8D7-337EDC1D616E

P1476

Q36302871-A7605613-6C83-4564-912E-5929C1E2777C

P2093

Q36302871-93A1835B-68B7-43F9-A28F-72B009E9E816

Q36302871-9B5BE35D-D7DA-442A-9C5C-BEEC09F25110

P2860

Q36302871-0983E7B6-14A4-46C4-9DEC-FCD17AD9D645

Q36302871-0B1B254C-747C-4F70-8364-3BFA5DCE1405

Q36302871-14E58CC7-4A0F-46D3-84CD-0CC096CCCEF1

Q36302871-2049451A-60FD-45F0-BA16-ABD130494784

Q36302871-21380934-55B2-4813-8485-8974EA77D6D2

Q36302871-240DD73E-33B8-4213-8BEC-11FD23B0584E

Q36302871-266B4AF3-D24D-4909-A660-2B7E24313132

Q36302871-271429B9-148B-460E-81B3-C00C3CA0E3D1

Q36302871-271FB0A1-4DD2-4BF8-949E-7D9D8496CCE8

Q36302871-27C4EBDB-529E-4942-90A3-A1AC92DF087C

P304

Q36302871-F6262D8C-970B-4C8E-A9C2-6F3C850CD775

P31

Q36302871-E11B489E-DACB-4989-BC03-F46E26961097

P356

Q36302871-E148B324-15CC-47BC-AA04-A157C369D0C3

P407

Q36302871-865FD1E1-C6DB-4A18-A643-EE3611CF0A5F

P433

Q36302871-8271EC4B-6D79-4A66-868F-44C311D4FCFA

P478

Q36302871-FBB5DB44-BD5B-46CA-BCC7-4BA79BCDAA41

P577

Q36302871-C4FB57B1-8516-4B52-9FEA-7E9A92F90A95

P698

Q36302871-B5BAE7BF-1A76-425B-BEC7-E27243958A03

P356

14728214.10.4.891

P1433

Expert Opinion on Emerging Drugs

P1476

Current and emerging therapies for the lysosomal storage disorders.

@en

P2093

Gregory M Pastores

http://www.w3.org/2001/XMLSchema#string

Natalie L Barnett

http://www.w3.org/2001/XMLSchema#string

P2860

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin

The mannose receptor family

Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease

Glycosphingolipidoses: beyond the enzymatic defect

A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates

Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.

Therapeutic apheresis in renal and metabolic diseases.

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.

P304

891-902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.10.4.891

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16262569

http://www.w3.org/2001/XMLSchema#string